US › Healthcare

Quince Therapeutics, Inc. (QNCX)

US · Healthcare · Biotechnology

$27.41+9.79%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$35.9M
Profit YoY
+338.9%
EPS
$-152.00
EPS estimate
$-45.00

EPS came in at -152.00 against a street estimate of -45.00 — a miss of 237.8%.

Key statistics

Market cap
$22.9M
Forward P/E
0.0
P/B
1.50
Book value
$22.73
EPS (TTM)
$-210.00
52-week high
$910.00
52-week low
$15.10
50-day MA
$19.53
200-day MA
$215.00
Beta
1.40

Analyst view

Analysts rate Quince Therapeutics, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $82.75.

Shareholding

Insiders
0.32%
Institutions
14.18%

Largest institutional holders

FundStake
Woodline Partners LP2.66%
Millennium Management LLC1.28%
Shay Capital LLC0.91%
Acadian Asset Management LLC0.90%
IEQ CAPITAL, LLC0.31%
BlackRock Inc0.24%
Vanguard Capital Management, LLC0.24%
State Street Corp0.13%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Quince Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.